Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA
Recent studies have shown that Helicobacter pylori infections are a major public health concern globally. According to the CDC, about two-thirds of the global population is infected with H. pylori. H. pylori infection is considered the leading cause for chronic gastritis and is also considered an etiological agent for gastric cancer (adenocarcinoma) and peptic ulcer disease.1-3 H. pylori infection has also been associated with mucosa-associated lymphoid tissue (MALT) and has been attributed to approximately 89% of gastric cancer diagnoses. 1, 4
- Hooi James KY,
Lai Wan Ying, Ng Wee Khoon, Suen Michael MY. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis, Gastroenterology. 2017; Vol 153, No. 2.
- Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–781.
- Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol. 2007;102:1789–1798.
International Agency for Research on CancerHelicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. (IARC Working Group Reports, No. 8). Lyon, France: International Agency for Research on Cancer, 2014. Available from: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Working-Group-Reports/-Em-Helicobacter-Pylori-Em-Eradication-As-A-Strategy-For-Preventing-Gastric-Cancer-2014. Accessed November 18, 2016.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
Chief Executive Officer
Source: Meridian Bioscience Inc.